Finally, in a subgroup of the current subjects, and controlling for neuropathologic burden, we reported a 32% decrease in MAP2 protein levels in AD+P subjects compared to AD–P subjects, while both AD phenotypes had significantly less MAP2 peptide levels than unaffected control subjects (15). The gene discussed is MAP2; the disease is Alzheimer disease.